26 articles
Combining methotrexate with a biologic or JAK inhibitor nearly doubles rheumatoid arthritis remission odds, per a major JAMA review of 123 studies.
A skin patch delivering low-dose theophylline to repair multiple sclerosis nerve damage is moving toward human clinical trials after promising mouse study.
The FDA approved brepocitinib, the first oral drug for dermatomyositis, cutting steroid dependence and improving symptoms in as little as four weeks.
Microglia activation in MS lesions predicts disability progression, offering doctors a powerful new biomarker to personalize treatment before damage.
A stroke drug called nimodipine may reduce inflammation and repair myelin damage in multiple sclerosis, according to a review of animal studies.
Australia's PBAC will review all PBS-listed multiple sclerosis medicines in 2026, with patient input shaping which treatments stay affordable and.
Rituximab outperforms other rheumatoid arthritis drugs for pain and fatigue relief, but a 99-study analysis finds treatment choice should match each.
The FDA has cleared Lucid-MS, the first oral multiple sclerosis drug designed to repair nerve damage rather than just suppress the immune system.
Lupus patients with low hydroxychloroquine blood levels face 47% higher cardiovascular risk, a new Yale study finds; regular blood level monitoring is key.
Three radical MS treatment approaches, from a one-time CAR T cell immune reset to gut bacteria supplements, could move beyond symptom management to tackle.
Filgotinib showed one-tenth the shingles risk of tofacitinib in a real-world study of rheumatoid arthritis patients on JAK inhibitors.
NHS England now offers fampridine for multiple sclerosis patients, with 43% walking faster, but only those who respond after a trial period continue.
Australian researchers are using lab-grown mini brains to study myelin repair in multiple sclerosis, a disease with no current treatment to reverse nerve.
A protein called Piezo2, found in 73% of healthy myelin cells but only 50% in MS tissue, could offer a new way to preserve nerve protection in multiple.
Updated MS diagnostic criteria could catch multiple sclerosis earlier, but experts warn of overdiagnosis risks and urgent need to redesign clinical trials.
A new psoriasis pill called zasocitinib cleared scalp lesions in 77% of patients in Phase 3 trials, far outperforming existing oral treatments.
Type 1 diabetes can now be detected and treated before symptoms appear, but experts warn that inconsistent screening limits access to this breakthrough.
Women with rheumatoid arthritis can now safely plan pregnancies, with 85% maintaining remission when kept on biologic medications throughout gestation.
UCLA scientists are engineering immune cells that attack multiple sclerosis on two fronts, with $7.49M in funding to push the potential cure toward human.
Two patients with a severe autoimmune disease remain symptom-free for over 15 years after a stem cell transplant fully replaced their immune systems.
A German biotech has enrolled all 63 patients in a trial testing MIC-Lx, a cell therapy designed to end lifelong immunosuppression after kidney transplant.
Europe's first systemic vitiligo treatment is nearly here: upadacitinib showed 75% facial repigmentation in trials and awaits final EU approval.
CAR T-cell therapy is achieving remission in severe autoimmune diseases like lupus and rheumatoid arthritis, with 83% of trial patients responding without.
Joe Manganiello's memoir will reveal a seven-year autoimmune battle that attacked five body systems and required life-saving organ removal.
A new genetic study links celiac disease to pulmonary arterial hypertension, a serious lung condition, suggesting the autoimmune disorder's risks extend.
Scientists used BiTE molecules to erase autoimmune disease at its root, reaching immune cells hiding in bone marrow where standard drugs cannot.
